Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users

By Amendola A.   Tanzi E.   Zappa A.   Colzani D.   Boschini A.   Musher D.M.   Zanetti A.R.  

Vaccine, Vol. 20, Iss. 31, 2002-11 ,pp. : 3720-3724

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of HIV-1 DNA constructs in chimpanzees

By Bagarazzi M.L.   Boyer J.D.   Ugen K.E.   Javadian M.A.   Chattergoon M.   Shah A.   Bennett M.   Ciccarelli R.   Carrano R.   Coney L.   Weiner D.B.  

Vaccine, Vol. 16, Iss. 19, 1998-11 ,pp. : 1836-1841

Elsevier

Access to resources Recommend Favorite

A Phase I safety and immunogenicity trial of UBI(R) microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects

By Lambert J.S.   Keefer M.   Mulligan M.J.   Schwartz D.   Mestecky J.   Weinhold K.   Smith C.   Hsieh R.   Moldoveanu Z.   Fast P.   Forrest B.   Koff W.  

Vaccine, Vol. 19, Iss. 23, 2001-04 ,pp. : 3033-3042

Elsevier

Access to resources Recommend Favorite

Influenza immunization for HIV-infected persons in Los Angeles

By Sorvillo F.J.   Nahlen B.L.  

Vaccine, Vol. 13, Iss. 4, 1995-01 ,pp. : 377-380

Elsevier

Access to resources Recommend Favorite

Lifetime hospitalization profiles for symptomatic, HIV-infected persons

By Dijkgraaf M.G.W.   Luijben A.H.P.   Postma M.J.   Borleffs J.C.C.   Schrijvers A.J.P.   Jager J.C.  

Health Policy, Vol. 35, Iss. 1, 1996-01 ,pp. : 13-32

Elsevier

Access to resources Recommend Favorite